---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-23-000090"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:20:40.444354+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio Q3 net loss $67.4M; restructuring charges $46.3M; cash runway beyond 2026

## Summary
- Net loss $67.4M ($0.52 per share) vs $56.2M ($0.43) in Q3 2022.
- Cash, equivalents, restricted cash and marketable securities $184.5M, down from $260.9M at Dec 31, 2022.
- Restructuring and impairment charges of $46.3M in Q3 2023; none in prior year.
- R&D expenses dropped to $8.5M from $39.7M reflecting pipeline reprioritization.
- Cash runway expected beyond 2026; ITIL-306 Phase 1 data in NSCLC anticipated in 2024.

## SEC filing metadata
- accession: 0001789769-23-000090
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/0001789769-23-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/til-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-23-000090
- JSON: https://secwatch.observer/filing/0001789769-23-000090.json
- Plain text: https://secwatch.observer/filing/0001789769-23-000090.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported the quarter ended September 30, 2023 results: net income Net loss $(67,432) (in thousands), EPS Net loss per share, basic and diluted $(0.52).
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss $(67,432) (in thousands)
  - EPS: Net loss per share, basic and diluted $(0.52)
  - Result: reported results
  source text: On November 13, 2023 , Instil Bio, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2023 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000090/0001789769-23-000090-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.